Format

Send to

Choose Destination
J Surg Oncol. 2017 May;115(6):647-662. doi: 10.1002/jso.24561. Epub 2017 Feb 17.

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.

Author information

1
Desert Surgical Oncology, Eisenhower Medical Center, Rancho Mirage, California.
2
VMWA LLC, Palo Alto, California.
3
Instituto Nacional de Cancerología, Bogota, Colombia.
4
Instituto Nacional de Cancerología, Mexico City, Mexico.
5
Universidade Estadual de Campinas, Campinas, Brazil.
6
Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina.
7
Centro Integral Oncológico Comprensivo Clara Campal, Madrid, Spain.
8
Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
9
Hospital Sírio-Libanes, Sao Paulo, Brazil.
10
Hospital Dr. Juan A. Fernandez, Buenos Aires, Argentina.

Abstract

Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

KEYWORDS:

adjuvant; biomarkers; breast neoplasms; chemotherapy; clinical decision-making; gene expression; genomics risk; prognosis; tumor

PMID:
28211064
PMCID:
PMC5484338
DOI:
10.1002/jso.24561
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center